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Take home message: This study reports on
the use of HFNC therapy in interhospital
transport of critically ill children. The
increasing use of HFNC was paralleled by a
decrease in invasive ventilation initiated by
the retrieval team.
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Abstract Purpose: Optimal
respiratory support for interhospital
transport of critically ill children is
challenging and has been scarcely
investigated. High-flow nasal cannula
(HFNC) therapy has emerged as a
promising support mode in the pae-
diatric intensive care unit (PICU), but
no data are available on HFNC used
during interhospital transport. We
aimed to assess the safety of HFNC
during retrievals of critically ill chil-
dren and its impact on the need for
invasive ventilation (IV). Meth-
ods: This was a retrospective,
single-centre study of children under
2 years old transported by a special-
ized paediatric retrieval team to
PICU. We compared IV rates before
(2005–2008) and after introduction of
HFNC therapy (2009–2012).
Results: A total of 793 infants were
transported. The mean transport
duration was 1.4 h (range 0.25–8),
with a mean distance of 205 km
(2–2,856). Before introduction of
HFNC, 7 % (n = 23) were retrieved
on non-invasive ventilation (NIV)
and 49 % (n = 163) on IV. After
introduction of HFNC, 33 %
(n = 150) were retrieved on HFNC,
2 % (n = 10) on NIV, whereas IV
decreased to 35 % (n = 162,
p \ 0.001). No patients retrieved on
HFNC required intubation during
retrieval, or developed pneumothorax
or cardiac arrest. Using HFNC was
associated with a significant reduction
in IV initiated by the retrieval team
(multivariate OR 0.51; 95 % CI
0.27–0.95; p = 0.032). Conclu-
sions: We report on a major change
of practice in transport of critically ill
children in our retrieval system.
HFNC therapy was increasingly used
and was not inferior to low-flow
oxygen or NIV. Randomized trials
are needed to assess whether HFNC
can reduce the need for IV in inter-
hospital transport of critically ill
children.
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Introduction
Respiratory diseases in childhood represent one of the
main reasons requiring transfer to a paediatric intensive
care unit (PICU) [1]. Traditionally, interhospital transport
teams tended to have a very low threshold for intubation
and invasive ventilation (IV), given the inherent diffi-
culties of escalating respiratory support whilst being on
road or air transport [2]. Intubation and ventilation are
associated with intrinsic risks, such as pneumothorax, and
endotracheal tube dislocation and obstruction. Patients
will require sedation and neuromuscular paralysis for
transport, and mechanical ventilation exposes the child to
ventilator-induced lung injury (VILI) [3], taking into
account that most transport ventilators are not as sophis-
ticated as modern PICU ventilators.
Over the past decade, the increasing use of non-inva-
sive ventilation (NIV) and, more recently, high-flow nasal
cannula (HFNC) therapy has led to a reduced need for IV
in intensive care units [4]. Given the side effects associ-
ated with IV, this approach is promising but the impact on
outcome still needs further evaluation [5]. HFNC therapy
is a non-invasive supportive air/oxygen therapy that has
been used with success in critically ill neonates, children
and adults [4, 6]. HFNC can provide a degree of contin-
uous positive airway pressure (CPAP), reduces the work
of breathing, and may have additional flow-related ben-
efits such as a reduction in anatomical dead space [7, 8].
In our PICU, HFNC therapy was shown to reduce intu-
bation rates from 37 to 7 % in infants with bronchiolitis,
which has been supported by other studies [9–12].
There is little evidence to guide strategies for optimal
respiratory management during interhospital transfer [13].
Previous small studies in neonates and children suggest
that the use of NIV is safe [14, 15]. To date, there are no
data on the use of HFNC therapy during transport of
paediatric patients. We present our experience of HFNC
therapy used for transporting critically ill children aged
below 2 years and report safety and outcome data, as well
as the impact of HFNC therapy on successive PICU
management of these patients.
Patients and methods
Study design
This was a single-centre, retrospective, observational
study investigating critically ill children under 2 years of
age who required interhospital transport by our special-
ized tertiary paediatric retrieval team and who were
consecutively admitted to our PICU (Mater Children’s
Hospital Brisbane, Australia) between 1 January 2005 and
31 December 2012. Children transported by other retrie-
val teams or children not requiring PICU admission were
excluded. The study was approved by the institutional
ethical review board (Mater Health Services Human
Research Ethics Committee) including waiver of
informed consent.
Data extraction
Data on the interhospital transfers were extracted from the
institutional retrieval system database, which prospec-
tively records demographic data, physiologic parameters,
medications, interventions, respiratory support, compli-
cations, and mode and timing of transport. Data were
verified by manually checking individual charts. Data on
the management and course in the PICU were extracted
from the PICU clinical information system (CIS). Diag-
nostic codes, Paediatric Index of Mortality 2 (PIM2)
scores [16] and severity indicators were extracted from
the Australian and New Zealand Paediatric Intensive Care
registry (ANZPIC) [17].
Paediatric retrieval system characteristics
The Mater Children’s PICU is the largest PICU in
Queensland, Australia, with ca. 1,300 admissions per
year, and covers an area extending from northern New
South Wales up to Cairns, with a population of approxi-
mately 4.5 million inhabitants. Each year, on average 400
critically ill children are retrieved by the Mater Children’s
PICU Retrieval Team. Until 2008, children requiring
respiratory support other than oxygen were treated with
IV or NIV (including CPAP and biphasic positive airway
pressure modes (BiPAP), delivered via mask or naso-
pharyngeal tube). In late 2008, given the positive
experience and safety profile of HFNC therapy used at our
PICU [9], it was decided to include HFNC therapy as a
ventilatory support technique for interhospital transfers.
Test runs confirmed the feasibility of its use during
transport. After 1 January 2009, HFNC therapy was
available as a standard treatment option in addition to IV
and NIV.
Definitions and outcomes
The modes of respiratory support during transport were
defined as (i) low flow oxygen/room air, (ii) HFNC
(defined as 2 L/kg/min flow with the use of nasal can-
nula), (iii) non-invasive ventilation (NIV, defined as
CPAP or BiPAP) and (iv) invasive ventilation (IV). Heart
rate, respiratory rate, oxygen saturation, FiO2 and the
level of respiratory support were extracted from the
database at four time points: first contact of the transport
team with the patient in the referring hospital; immedi-
ately prior to leaving the referring hospital; at arrival to
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PICU; and 24 h after admission to PICU. We compared
the use of the respiratory support modes and the com-
plication rates in a 48-month period pre-HFNC
introduction (1 January 2005–31 December 2008) versus
a 48-month period post-HFNC introduction (1 January
2009–31 December 2012). Adverse events during trans-
port were defined as need for intubation, pneumothorax,
cardiac arrest requiring cardiopulmonary resuscitation
(CPR), and death. A secondary outcome was the need for
IV during the first 24 h after PICU admission. The prin-
cipal diagnosis requiring interhospital transfer was
extracted from the ANZPIC registry, and was classified
into respiratory conditions (bronchiolitis, pneumonia,
apnoea, upper airway obstruction and other lung dis-
eases), neurologic conditions (including seizures,
encephalopathy and neuromuscular disorders), cardiac
conditions, trauma, sepsis and other causes.
HFNC set-up
HFNC was delivered through paediatric specific nasal
cannulae (neonatal, infant, paediatric size; Fisher &
Paykel Healthcare Ltd., Auckland, New Zealand) which
were connected to a heated humidifier (Fisher & Paykel
Healthcare Ltd., Auckland, New Zealand) through a
paediatric circuit kit (Fisher & Paykel Healthcare Ltd.,
Auckland, New Zealand) (see figure in Electronic Sup-
plementary Material).
Statistics
Means and 95 % confidence intervals are reported.
Independent t test and Chi-squared test were used to
assess differences between the two periods. For small
samples and non-parametric distributed data, the Mann–
Whitney U test was used. Logistic regression was used to
model the need for IV and IV/NIV. For multivariate
models, covariates that had shown a trendwise association
with the need for IV were selected. In the final models,
the period pre/post-HFNC, age, transport distance, mode
of transport (ground, rotary wing, fixed wing), disease
group and PIM2 scores were used as covariates. SPSS
18.0 software was used. P values less than 0.05 were
considered significant.
Results
Comparison of pre-HFNC versus post-HFNC period
In total, 793 children below 2 years of age were retrieved
to PICU, 331 in the pre-HFNC period and 462 in the post-
HFNC period (40 % increase, Table 1). During the same
period, the total number of PICU admissions had
increased by 55 %. The mean duration of transport was
1.4 h (range 0.25–8), with a distance of 205 km
(2–2,856). Before introduction of HFNC therapy, 7 %
(n = 23) were transported on NIV and 49 % (n = 163)
on IV (Figs. 1, 2). A total of 119 (36 %) children had
been intubated prior to arrival of the PICU retrieval team,
and 44 (13 %) were intubated in the referring hospital by
the retrieval team. After introduction of HFNC therapy,
33 % (n = 150) were transported on HFNC and 2 %
(n = 10) on NIV, whereas IV decreased to 35 %
(n = 162, p \ 0.001). During this period, 128 (28 %)
children were already intubated at baseline, whereas 34
(7 %) were intubated in the referring hospital by the PICU
retrieval team. When restricting analyses to patients with
bronchiolitis, both the absolute and relative number of
infants requiring IV initiated by the retrieval team
decreased between the two periods (34/102 (33 %) versus
26/169 (15 %), p = 0.001). Similarly, the rate of infants
with bronchiolitis requiring IV/NIV decreased signifi-
cantly (50/102 (49 %) versus 31/169 (18 %), p \ 0.001).
Adverse effects during interhospital transport
and safety of HFNC
In the pre-HFNC period, two children required CPR
during transport. In the post-HFNC period, no patient
required intubation during retrieval, and one already
intubated child with septic shock required CPR. No
patient developed a pneumothorax or died during trans-
port during the entire study period.
In total, 150 children were retrieved on HFNC therapy
post-HFNC introduction, covering distances of
25–744 km (mean 96 km) with transport duration of up to
4 h. Bronchiolitis (77 %) was the predominant condition
requiring transport, and 144/150 (94 %) children retrieved
on HFNC suffered from a respiratory condition (Table 2).
Two patients retrieved on HFNC were escalated to NIV
during the retrieval. Sedation was given to 1 % (n = 2) of
children retrieved on HFNC; in contrast 97 % of infants
on NIV or IV were given sedation.
Escalation of respiratory support after admission
to PICU
The rate of retrieved children requiring intubation for
respiratory reasons during the first 24 h after PICU
admission did not change significantly between the two
periods (pre-HFNC 5/331 (2 %) versus post-HFNC
12/462 (3 %), p = 0.30). The rate of retrieved children
requiring initiation of NIV during the first 24 h after
admission was reduced from 20/331 (6 %) to 14/462
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(3 %) after introduction of HFNC (p = 0.039). Three of
150 (2 %) infants retrieved on HFNC therapy required
intubation during the first 24 h after PICU admission due
to respiratory reasons, and 9 (6 %) were escalated to NIV.
Multivariate models
The need for IV initiated by the retrieval team was
significantly reduced post-HFNC therapy introduction
even after adjusting for age, transport distance, transport
modality, disease group and PIM2 score (odds ratio, OR
0.51, 95 % CI 0.27–0.95, p = 0.032, Table 3). Simi-
larly, the rate of NIV or IV initiated by the retrieval
team was significantly lower in the period 2009–2012
compared to the period prior to HFNC (OR 0.36, 95 %
CI 0.22–0.60, p \ 0.001). Sensitivity analyses restricted
to infants with respiratory disease gave similar results
(data not shown).
Discussion
We observed an important change in practice in respiratory
support in critically ill infants under 2 years of age trans-
ferred by a specialized paediatric retrieval team. This
finding parallels the general trend observed in paediatric
critical care settings to early use of NIV in children with
severe respiratory disease [11]. To the best of our knowl-
edge, this is the first study reporting the use of HFNC
therapy in transport medicine. Our data based on a single-
centre, retrospective study indicate that the increasing use
of HFNC therapy during transport in selected critically ill
infants did not lead to an increased rate of complications.
Further studies are needed to confirm our observation of a
decrease in IV after the introduction of HFNC.
Safety of HFNC therapy during transport
There is a lack of studies describing the safety and quality
of respiratory support in critically ill paediatric patients
requiring interhospital transport [1, 18, 19]. Our
Table 1 Baseline and
demographic data comparing
infants retrieved prior to
introduction of high-flow nasal
cannulae (HFNC) versus infants
retrieved after HFNC
introduction
Pre HFNC
(n = 331)
Post HFNC
(n = 462)
p value*
Weight (kg) 6.4 (1.9–15.0) 6.6 (2.1–16.0) 0.46
Age (months) 6.2 (0.0–24) 6.5 (0.0–24) 0.47
Transport duration (h) 1.4 (0.1–8.8) 1.4 (0.1–5.0) 0.72
Transport distance (km) 191 (2–2,856) 214 (6–1,819) 0.41
Mode of transport 0.97
Road 217 (66 %) 300 (65 %)
Helicopter 67 (20 %) 94 (20 %)
Fixed wing 47 (14 %) 68 (15 %)
Main cause requiring retrieval 0.037
Respiratory 170 (51 %) 262 (57 %) 0.14
Neuromuscular 54 (16 %) 49 (11 %)
Cardiac 25 (8 %) 41 (9 %)
Trauma 15 (5 %) 11 (2 %)
Sepsis 6 (2 %) 18 (4 %)
Others 61 (18 %) 81 (18 %)
Patient severity
PIM2 score 5.9 % (0.16–94.6 %) 5.3 % (0.07–99.3) 0.55
PICU LOS (days) 4.4 (0.1–135) 4.3 (0.1–215) 0.87
Hospital LOS (days) 12.6 (0.1–263) 11.6 (0.1–308) 0.52
Data are reported as N (%) or mean (range)
PIM2 Paediatric Index of Mortality 2, LOS length of stay
* p value of Chi-squared test (for ratios) and p value of Student’s t test (for linear variables)
Fig. 1 Mode of respiratory support during the study period
2005–2012. The percentual use of each mode of transport is
shown. The arrow indicates the introduction of high-flow nasal
cannulae (HFNC) as a standard respiratory support option into the
retrieval team. NIV non-invasive ventilation, IV invasive ventilation
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retrospective study showed that, in general, complications
during transport of children under 2 years of age are very
rare: out of 793 children transported over 8 years only
three needed a major intervention such as intubation or
CPR during transport. This is a surprisingly low number
considering that the geographic area covered by our
retrieval system is likely among the largest in the world.
We have not observed any increase in complications since
the regular use of HFNC therapy during retrievals was
initiated. Importantly, the safety profile of HFNC was
excellent and we did not observe any major side effects
[20]. In addition, the rate of children requiring intubation
for respiratory reasons after being admitted to PICU did
not increase after the introduction of HFNC therapy. Our
data thus do not support the concern that children who are
transported on HFNC therapy receive delayed definitive
care such as IV.
Impact of HFNC therapy on intubation rates
We observed a twofold reduction in intubations per-
formed by the retrieval team when comparing a 4-year
period prior to use of HFNC therapy in retrievals versus
a 4-year period after HFNC therapy became available.
Since the proportion of infants that were already intu-
bated by the referring hospital prior to arrival of the
retrieval team had dropped from 36 to 28 %, it is unli-
kely that a change in intubation practice in the referring
hospitals would account for reduced intubations by the
retrieval team. We cannot exclude that changes in
Fig. 2 Flow chart comparing
respiratory support between the
two study periods. HFNC high-
flow nasal cannulae, NIV non-
invasive ventilation
Table 2 Characteristics of infants retrieved on high-flow nasal
cannula (HFNC) during the study period
HFNC (n = 150)
Weight (kg) 6.7 (2.3–13.5)
Age (months) 6.2 (0.3–23)
Transport duration (h) 1.2 (0.1–3.8)
Transport distance (km) 96 (25–744)
Mode of transport
Road 117 (78 %)
Helicopter 25 (17 %)
Fixed wing 8 (5 %)
Main cause requiring retrieval
Bronchiolitis 115 (77 %)
Respiratory non-bronchiolitis 25 (17 %)
Neuromuscular 3 (2 %)
Cardiac 1 (1 %)
Trauma 0 (0 %)
Sepsis 4 (3 %)
Others 2 (1 %)
Patient severity
PIM2 score 0.4 % (0.16–4.0 %)
PICU LOS (days) 2.4 (0.2–10)
Hospital LOS (days) 8.0 (1.6–150)
Data are reported as N (%) or mean (range)
PIM2 Paediatric Index of Mortality 2, LOS length of stay
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patient mix may have affected the observed reduction in
intubations. However, not only the relative but as well
the absolute number of IV/NIV initiated by the retrieval
team decreased after introduction of HFNC, and the
same finding was observed in subgroup analyses
restricted to infants with respiratory diseases and with
bronchiolitis. In addition, the mean patient age, transport
characteristics and severity indicators such as PIM2
scores and length of stay did not significantly change
between the periods. The rate of infants failing HFNC
therapy was low and only 2 % required intubation for
respiratory reasons after admission. Most infants man-
aged on HFNC therapy did not require any sedation,
suggesting HFNC was well tolerated. These findings are
supported by previous studies reporting on the use of
HFNC therapy in PICU patients [9, 10, 21, 22]. While
randomized controlled studies on HFNC in infants are
lacking, a recent randomized controlled trial in very
preterm neonates reported non-inferiority of HFNC to
CPAP [23].
It is known that children admitted to PICU have a
higher mortality if they have been retrieved [24], which
may be related to a variety of factors such as selection
bias, delays in presentation and in initiation of appropriate
treatment, and diagnostic challenges under remote health-
care conditions. Furthermore, the low threshold for IV
that many retrieval teams apply may expose children to
the risks of IV, and potential impacts of sedation on the
developing brain. It is therefore important to evaluate
whether initiation of intensive care treatment at an early
stage may potentially succeed in limiting disease pro-
gression. Owing to the inherent properties of the infant
respiratory system with small airways and high chest
compliance, the risk of developing atelectasis is high in
bronchiolitis [25]. HFNC therapy applied early in the
disease process may prevent progression of the disease
and maintain normal lung volumes, thereby preventing
atelectasis [26]. As a result, the functional residual
capacity can be maintained and work of breathing
reduced, which may stabilize the patient sufficiently to
avoid the need for intubation. For this purpose we used
flow rates of 2 L/kg/min which have been shown to result
in a positive end-expiratory pressure of 4–5 cmH2O [8,
25].
Limitations
Firstly, since this is not a randomized controlled trial, we
cannot rule out that differences in the patient population
accounted for the observed decrease in intubations.
However, multivariate analyses adjusted for important
potential confounders, including patient severity as mea-
sured by PIM2 score, confirmed the main results, as did
subgroup analyses limited to infants with bronchiolitis.
Secondly, the experience in our unit that HFNC is well
tolerated and has an excellent safety profile [9] provided
the basis for the early use of HFNC by our retrieval team.
It is thus possible that the increase in infants retrieved on
HFNC may partially represent overtreatment of some
patients that hypothetically would have done well on low-
flow oxygen. Yet, the increase of interhospital transfers
observed in this study mirrors the growth of our PICU in
the past decade which is attributable to populational
growth and to the expansion of tertiary paediatric services
including cardiac surgery and extracorporeal membrane
oxygenation (ECMO). Thirdly, the study was not
Table 3 Uni- and multivariate logistic regression models analysing risk factors associated with intubation, and with intubation/non-
invasive ventilation initiated by the retrieval team
Variable Univariate p value Multivariate p value
OR [95 % CI] OR [95 % CI]
Intubation by retrieval team
Distance (100 km) 1.05 [0.99–1.12] 0.11 1.02 [0.90–1.17] 0.80
Respiratory disease 0.75 [0.46–1.21] 0.24 3.76 [1.89–7.49] \0.001
PIM 2 (tercile) 9.32 [5.82–14.91] \0.001 14.44 [8.19–25.47] \0.001
Rotary wing 3.02 [1.75–5.22] \0.001 3.51 [1.72–7.16] 0.001
Fixed wing 2.18 [1.10–4.29] 0.025 1.26 [0.40–4.03] 0.69
Age (month) 0.95 [0.91–1.00] 0.04 0.95 [0.90–1.01] 0.074
HFNC period 2009–2012 0.43 [0.27–0.70] 0.001 0.51 [0.27–0.95] 0.032
Intubation or non-invasive ventilation by retrieval team
Distance (100 km) 1.03 [0.97–1.10] 0.32 1.03 [0.92–1.15] 0.63
Respiratory disease 1.14 [0.74–1.76] 0.56 3.82 [2.12–6.85] \0.001
PIM 2 (tercile) 3.81 [2.72–5.33] \0.001 5.67 [3.75–8.57] \0.001
Rotary wing 2.38 [1.47–3.84] \0.001 2.49 [1.40–4.45] 0.002
Fixed wing 1.44 [0.77–2.69] 0.25 0.90 [0.33–2.51] 0.84
Age (month) 0.94 [0.91–0.98] 0.003 0.95 [0.91–0.99] 0.02
HFNC period 2009–2012 0.33 [0.21–0.50] \0.001 0.36 [0.22–0.60] \0.001
Infants already intubated prior to arrival of the retrieval team were excluded
OR odds ratio, 95 % CI 95 % confidence interval, PIM Paediatric Index of Mortality 2, HFNC high-flow nasal cannula
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powered to detect significant differences in major adverse
events occurring at a low rate. Fourthly, it is important to
mention that unique features of the Queensland Paediatric
Retrieval Service need to be considered which may
impact on the generalizability of our findings to other
services: Our service is run by a fully dedicated special-
ized paediatric intensive care retrieval team and often
performs retrievals over long distances. In addition, our
PICU has acquired several years of experience with
HFNC therapy prior to implementing this support mode in
transport medicine.
Strengths of this study include the relatively large
sample size and the adjustment of analyses for potential
confounders. This study is the first to assess the safety and
efficacy of HFNC therapy in retrievals. Transport medi-
cine, particularly in the field of paediatric critical care, is
often treated as an orphan discipline [27], and clinical
practice and technological developments often lag con-
siderably behind innovations that have already been
implemented in the PICU. Only recently, a large study
from the UK demonstrated that increased professionalism
in paediatric retrieval teams was associated with
improved survival [1]. Our study demonstrates that the
application of a simple method of respiratory support is
safe and may potentially lead to improved outcomes.
On the basis of this experience, our paediatric retrieval
coordinators now recommend referring centres to initiate
HFNC therapy early in infants with moderate work of
breathing. Patient response to HFNC therapy can be
assessed upon arrival of the retrieval team in the referring
hospital which allows for stratification of patients into
responders/non-responders [9].
Conclusion
We report on a major change of practice observed in
respiratory support in interhospital transport of critically
ill children in our retrieval system. HFNC therapy was
increasingly used and was well tolerated, easy to perform
and showed a good safety profile. Our observation of a
reduction in intubation rates demonstrates that HFNC
therapy is not inferior to the practice of using low-flow
oxygen or NIV. Randomized controlled trials are urgently
needed to assess whether HFNC therapy may indeed
reduce the need for IV in interhospital transport of criti-
cally ill children.
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